Literature DB >> 23797736

Integrated molecular analysis of clear-cell renal cell carcinoma.

Yusuke Sato1, Tetsuichi Yoshizato, Yuichi Shiraishi, Shigekatsu Maekawa, Yusuke Okuno, Takumi Kamura, Teppei Shimamura, Aiko Sato-Otsubo, Genta Nagae, Hiromichi Suzuki, Yasunobu Nagata, Kenichi Yoshida, Ayana Kon, Yutaka Suzuki, Kenichi Chiba, Hiroko Tanaka, Atsushi Niida, Akihiro Fujimoto, Tatsuhiko Tsunoda, Teppei Morikawa, Daichi Maeda, Haruki Kume, Sumio Sugano, Masashi Fukayama, Hiroyuki Aburatani, Masashi Sanada, Satoru Miyano, Yukio Homma, Seishi Ogawa.   

Abstract

Clear-cell renal cell carcinoma (ccRCC) is the most prevalent kidney cancer and its molecular pathogenesis is incompletely understood. Here we report an integrated molecular study of ccRCC in which ≥100 ccRCC cases were fully analyzed by whole-genome and/or whole-exome and RNA sequencing as well as by array-based gene expression, copy number and/or methylation analyses. We identified a full spectrum of genetic lesions and analyzed gene expression and DNA methylation signatures and determined their impact on tumor behavior. Defective VHL-mediated proteolysis was a common feature of ccRCC, which was caused not only by VHL inactivation but also by new hotspot TCEB1 mutations, which abolished Elongin C-VHL binding, leading to HIF accumulation. Other newly identified pathways and components recurrently mutated in ccRCC included PI3K-AKT-mTOR signaling, the KEAP1-NRF2-CUL3 apparatus, DNA methylation, p53-related pathways and mRNA processing. This integrated molecular analysis unmasked new correlations between DNA methylation, gene mutation and/or gene expression and copy number profiles, enabling the stratification of clinical risks for patients with ccRCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23797736     DOI: 10.1038/ng.2699

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  57 in total

1.  BLAT--the BLAST-like alignment tool.

Authors:  W James Kent
Journal:  Genome Res       Date:  2002-04       Impact factor: 9.043

Review 2.  Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect.

Authors:  Naoto Kuroda; Shuji Mikami; Chin-Chen Pan; Ronald J Cohen; Ondrej Hes; Michal Michal; Yoji Nagashima; Yukichi Tanaka; Keiji Inoue; Taro Shuin; Gang-Hong Lee
Journal:  Histol Histopathol       Date:  2012-02       Impact factor: 2.303

3.  Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma.

Authors:  Wing-Kin Sung; Hancheng Zheng; Shuyu Li; Ronghua Chen; Xiao Liu; Yingrui Li; Nikki P Lee; Wah H Lee; Pramila N Ariyaratne; Chandana Tennakoon; Fabianus H Mulawadi; Kwong F Wong; Angela M Liu; Ronnie T Poon; Sheung Tat Fan; Kwong L Chan; Zhuolin Gong; Yujie Hu; Zhao Lin; Guan Wang; Qinghui Zhang; Thomas D Barber; Wen-Chi Chou; Amit Aggarwal; Ke Hao; Wei Zhou; Chunsheng Zhang; James Hardwick; Carolyn Buser; Jiangchun Xu; Zhengyan Kan; Hongyue Dai; Mao Mao; Christoph Reinhard; Jun Wang; John M Luk
Journal:  Nat Genet       Date:  2012-05-27       Impact factor: 38.330

4.  Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.

Authors:  A Ari Hakimi; Ying-Bei Chen; James Wren; Mithat Gonen; Omar Abdel-Wahab; Adriana Heguy; Han Liu; Shugaku Takeda; Satish K Tickoo; Victor E Reuter; Martin H Voss; Robert J Motzer; Jonathan A Coleman; Emily H Cheng; Paul Russo; James J Hsieh
Journal:  Eur Urol       Date:  2012-09-27       Impact factor: 20.096

5.  Human mutation rate associated with DNA replication timing.

Authors:  John A Stamatoyannopoulos; Ivan Adzhubei; Robert E Thurman; Gregory V Kryukov; Sergei M Mirkin; Shamil R Sunyaev
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

6.  Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.

Authors:  Payal Kapur; Samuel Peña-Llopis; Alana Christie; Leah Zhrebker; Andrea Pavía-Jiménez; W Kimryn Rathmell; Xian-Jin Xie; James Brugarolas
Journal:  Lancet Oncol       Date:  2013-01-16       Impact factor: 41.316

7.  Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II.

Authors:  T Aso; W S Lane; J W Conaway; R C Conaway
Journal:  Science       Date:  1995-09-08       Impact factor: 47.728

8.  CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.

Authors:  Aikseng Ooi; Karl Dykema; Asif Ansari; David Petillo; John Snider; Richard Kahnoski; John Anema; David Craig; John Carpten; Bin-Tean Teh; Kyle A Furge
Journal:  Cancer Res       Date:  2013-01-30       Impact factor: 12.701

9.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.

Authors:  Cigall Kadoch; Diana C Hargreaves; Courtney Hodges; Laura Elias; Lena Ho; Jeff Ranish; Gerald R Crabtree
Journal:  Nat Genet       Date:  2013-05-05       Impact factor: 38.330

10.  Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.

Authors:  Tatsuhiro Shibata; Tsutomu Ohta; Kit I Tong; Akiko Kokubu; Reiko Odogawa; Koji Tsuta; Hisao Asamura; Masayuki Yamamoto; Setsuo Hirohashi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

View more
  462 in total

Review 1.  Molecular genetics and clinical features of Birt-Hogg-Dubé syndrome.

Authors:  Laura S Schmidt; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

Review 2.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

3.  A Three-microRNA Panel in Serum: Serving as a Potential Diagnostic Biomarker for Renal Cell Carcinoma.

Authors:  Guocheng Huang; Xinji Li; Zebo Chen; Jingyao Wang; Chunduo Zhang; Xuan Chen; Xiqi Peng; Kaihao Liu; Liwen Zhao; Yongqing Lai; Liangchao Ni
Journal:  Pathol Oncol Res       Date:  2020-06-18       Impact factor: 3.201

Review 4.  The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.

Authors:  Lili Liao; Joseph R Testa; Haifeng Yang
Journal:  Cancer Genet       Date:  2015-02-20

Review 5.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

6.  Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity.

Authors:  Joshua D Ochocki; Sanika Khare; Markus Hess; Daniel Ackerman; Bo Qiu; Jennie I Daisak; Andrew J Worth; Nan Lin; Pearl Lee; Hong Xie; Bo Li; Bradley Wubbenhorst; Tobi G Maguire; Katherine L Nathanson; James C Alwine; Ian A Blair; Itzhak Nissim; Brian Keith; M Celeste Simon
Journal:  Cell Metab       Date:  2018-05-10       Impact factor: 27.287

7.  Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.

Authors:  James J Hsieh; David Chen; Patricia I Wang; Mahtab Marker; Almedina Redzematovic; Ying-Bei Chen; S Duygu Selcuklu; Nils Weinhold; Nancy Bouvier; Kety H Huberman; Umesh Bhanot; Michael S Chevinsky; Parul Patel; Patrizia Pinciroli; Helen H Won; Daoqi You; Agnes Viale; William Lee; A Ari Hakimi; Michael F Berger; Nicholas D Socci; Emily H Cheng; Jennifer Knox; Martin H Voss; Maurizio Voi; Robert J Motzer
Journal:  Eur Urol       Date:  2016-10-15       Impact factor: 20.096

Review 8.  Renal Cell Carcinoma: Molecular Aspects.

Authors:  Aman Kumar; Niti Kumari; Vinny Gupta; Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2017-11-13

Review 9.  Precision medicine from the renal cancer genome.

Authors:  Yasser Riazalhosseini; Mark Lathrop
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

Review 10.  Filtering through the role of NRF2 in kidney disease.

Authors:  Cody J Schmidlin; Matthew B Dodson; Donna D Zhang
Journal:  Arch Pharm Res       Date:  2019-08-01       Impact factor: 4.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.